FDA Issues Class 2 Recall of Abbott Amulet LAA Occluder: All Lots Affected as Updated IFU Adds Pulmonary Artery Injury Distance Criterion

Event Overview

On 16 October 2026, the U.S. Food and Drug Administration (FDA) published a Class 2 recall of Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder in its medical device recall database. The recall number is Z-0191-2027, the event number is 99844, and the record corresponds to PMA number P200049 under product code NGV.

This is a labeling-level recall, not a batch defect. Records show that the firm initiated the action on 10 September 2026, and that the FDA published and classified it on 16 October 2026. The current status is classified and not yet terminated. The affected scope is eight models (9-ACP2-007-016 through 9-ACP2-010-034), designated as all lots and all serial numbers.

• Recall number: Z-0191-2027
• Event number: 99844
• PMA number: P200049; product code NGV
• Classification: Class II
• Firm-initiated date: 10 September 2026
• FDA publication and classification date: 16 October 2026
• Scope: 8 models, all lots and all serial numbers

The Substance of the Recall Is an IFU Update

The FDA records the reason for the recall as a change to the Instructions for Use (IFU) concerning the risk of Pulmonary Artery Injury (PAI). The reason category determined by the FDA is labeling design. The firm had posted the updated U.S. version of the IFU to manuals.eifu.abbott on 4 September 2026 and began notifying relevant customers from 10 September 2026.

The action is unrelated to lot quality. The issue identified is that the previous IFU did not adequately describe the intra-procedural risk.

The New Three-Tier Distance Criterion

The updated IFU introduces an actionable imaging criterion: once the landing zone has been determined, the closest distance between that zone and the pulmonary artery must be assessed.

• Less than or equal to 1.5 mm: considered a significant risk of pulmonary artery injury
• 1.5 mm to 3.0 mm: considered a theoretical risk
• Greater than 3.0 mm: considered a low risk

Where the distance falls within the high-risk range, an alternative landing zone or a change in device orientation should be considered, provided the C.L.O.S.E. criteria can still be met. If the risk cannot be adequately reduced, the operator should carefully evaluate whether implantation should proceed.

Why the Recall Was Classified as Class II

Under the FDA's recall classification framework, Class I applies where use of a device may cause serious adverse health consequences or death and the probability of such harm is not low. Class II applies where use may cause temporary or medically reversible adverse health consequences, or where the probability of serious harm is low.

The Class II determination is consistent with a risk scenario that is clearly defined and can be avoided through pre-procedural measurement and procedural planning. Class II does not mean the action can be disregarded: users are still required to carry out the actions described in the notification and to maintain records at the inventory and patient-record levels.

The Implication Extends Beyond a Single Manufacturer

Treating the IFU as a final page of text is a common industry habit. This event signals the opposite. Where postmarket information indicates that a complication is associated with anatomical conditions, and the existing IFU does not provide an executable screening method, a regulator can categorize this as a labeling design deficiency and trigger the recall process, even where product design, manufacturing processes and lot quality remain unchanged.

For companies preparing a U.S. PMA or 510(k), this means that labeling review will scrutinize whether risk information is actionable: whether explicit quantitative thresholds exist, and whether an operator reading the IFU can reach the same judgment.

Three Checks for Exporting Manufacturers

• Consistency between the risk management file and the IFU. Are the complications identified in the risk management report translated into operator-executable steps in the IFU, rather than reduced to a single statement that they may occur?
• Quantitative parameters. Wherever recommendations involve anatomical distance and size selection, provide numerical ranges or a decision pathway that can be followed step by step.
• Version control. Once the IFU is updated, regulatory submissions, the electronic IFU system, paper copies held in distributor inventory and hospital training materials must be synchronized; otherwise clinical practice may continue under the superseded version.

Actions at the Point of Use

At the hospital and distributor level, the first step is to verify products on hand by model and UDI-DI and confirm that inventory of all eight models falls within the notification scope. The second step is to confirm that operators have received the new IFU and that measurement of the distance to the pulmonary artery has been added to the pre-procedural imaging assessment. Previously implanted cases do not need to be retrieved, but the assessment conditions at the time may be noted in follow-up records. Institutions using an electronic IFU system should confirm that the version has been switched and retain the switch date.

AIMEILI Regulatory Interpretation

This case is a clear example of labeling being treated as a regulated risk-control output rather than a documentation formality. Under ISO 14971, information for safety is a risk control option, and it must be verified for effectiveness. When a manufacturer introduces a quantitative, operator-executable criterion such as the three-tier pulmonary artery distance threshold, the change should be traceable through the risk management file, the human factors and usability documentation, and the labeling itself. The FDA's decision to record the reason category as labeling design indicates that the deficiency was assessed as a gap in the content and usability of the instructions, not as a product performance failure.

For regulatory affairs teams, three points follow:

• US market: an IFU-only change is not automatically exempt from premarket procedures. Whether a PMA supplement, a 30-day notice or a report under 21 CFR 806 applies depends on the nature of the change, and the assessment should be documented before implementation. Recall status is also publicly searchable in the FDA database, which means the action becomes visible to procurement and tender processes.
• EU market: an IFU change affecting risk information for a Class III device is generally a significant change requiring notified body involvement, and the corresponding Field Safety Corrective Action and vigilance reporting obligations should be evaluated in parallel so that the two regions are not managed in isolation.
• Other markets: where the same device platform is registered elsewhere, the manufacturer should assess whether the updated labeling triggers a notification or variation, and whether local distributors hold paper IFUs that must be replaced.

The wider lesson is that physiological or anatomical parameters left as qualitative statements create regulatory exposure. Thresholds, decision pathways and the criteria an operator applies in the procedure should be written so that independent readers reach the same conclusion.

Business Impact

For Abbott, the operational burden is concentrated in documentation and field communication rather than in product returns or clinical retrieval: all lots and serial numbers are in scope, so distributors and hospitals must reconcile stock by model and UDI-DI, confirm receipt of the new IFU, and update training materials. Because the recall is classified and not terminated, it will remain visible in the FDA database and in customer due-diligence checks.

For competing LAA occluder manufacturers, the action raises the bar on labeling content. Sponsors with devices implanted in anatomically adjacent positions should review whether their own IFUs provide measurable screening criteria for pulmonary artery or adjacent-structure injury, and whether that review is documented. In the near term, expect reviewers to ask similar questions in pending and future submissions, and expect hospital value-analysis and tender questionnaires to reference publicly listed recalls during supplier evaluation.

For distributors and CROs supporting clients in the U.S. market, the practical priorities are version control and evidence of field action completion: records showing which customers were notified, when the electronic IFU version was switched, and how hospital training was updated. These records are frequently requested during audits and inspections and are the primary evidence that a labeling-level recall has been effectively executed.

Sources and Scope of Verification

Sources: U.S. Food and Drug Administration (FDA), Class 2 Device Recall Amplatzer Amulet, recall number Z-0191-2027, published and classified on 16 October 2026, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=222724; FDA medical device recall database search page, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm.

Scope of verification and access date: The recall record page (including the recall reason, the FDA-determined reason, firm actions, affected models and UDI-DI, and distribution scope) and the database search results page were reviewed. The access date was 20 October 2026. No media reports were used as factual sources. This article was originally published on 20 October 2026.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. Recall status and details may change as official updates are issued; execution should follow the original FDA record and the manufacturer's customer notification.